TG in PRP of patients with NSTEMI treated with clopidogrel in the presence or absence of VLD rivaroxaban. (A) Representative tracings of TG in PRP of patients with NSTEMI before (baseline) and after medication with clopidogrel + ASA at d1 in the absence (DMSO) or presence of 40 ng/mL rivaroxaban (in vitro), as well as after medication with clopidogrel + ASA and 2.5 mg rivaroxaban twice daily at d2 (in vivo) with resting platelets and (C) with 10 µg/mL CRP-stimulated platelets. (B) Arithmetic means ± SEM (n = 20) of lag time, TTP, peak (thrombin), and velocity of TG in PRP of patients with NSTEMI before (baseline) and after medication with clopidogrel + ASA at d1 in the absence (DMSO) or presence of 40 ng/mL rivaroxaban (in vitro) as well as after medication with clopidogrel + ASA and 2.5 mg rivaroxaban twice daily at d2 (in vivo) with resting platelets and (D) with 10 µg/mL CRP-stimulated platelets. *P < .05, **P < .01, and ***P < .001 indicate statistically significant differences from solvent control at the indicated time point. #P < .05 and ###P < .001 indicate significant differences from baseline.